Cytostatic drugs in infants: A review on pharmacokinetic data in infants

Cancer Treatment Reviews

Volumn 38, Issue 1, 2012, Pages 3-26

  Van den Berg, Hendrik ^a,b   van den Anker, John N ^c,d,e   Beijnen, Jos H ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Allometric scaling; Children; Cytostatic drugs; Infant; Infants; Metabolism; Oncology; Ontogeny; Pharmacokinetics; Pharmacotherapy

Indexed keywords

ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALDEHYDE OXIDASE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A; CYTOCHROME P450 2B6; CYTOCHROME P450 2E1; DACARBAZINE; DIMETHYLANILINE MONOOXYGENASE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IFOSFAMIDE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; PROCARBAZINE; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; CARDIOTOXICITY; DOWN SYNDROME; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INFANT; LEUKEMIA; LIVER BLOOD FLOW; NEUROTOXICITY; NONHODGKIN LYMPHOMA; REVIEW; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMPOUNDING; DRUG DOSAGE CALCULATIONS; HUMANS; INFANT; KIDNEY; LIVER; METABOLIC DETOXICATION, DRUG; NEOPLASMS;

EID: 83055175539     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.03.005     Document Type: Review

References (363)

1. Woods W.G., O'Leary M., Nesbit M.E. Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia. J Pediatr 1981, 98:642-645.
2. Allen J.C. The effects of cancer therapy on the nervous system. J Pediatr 1978, 93:903-909.
3. Reaman G., Zeltzer P., Bleyer W.A., Amendola B., Level C., Sather H., et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol 1985, 3:1513-1521.
4. Jones B., Breslow N.E., Takashima J. Toxic deaths in the Second National Wilms' Tumor Study. J Clin Oncol 1984, 2:1028-1033.
5. Arndt C., Hawkins D., Anderson J.R., Breitfeld P., Womer R., Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 2004, 22:1894-1901.
6. Reaman G.H. Special considerations for the infant with cancer. Pediatric Oncology 1989, 263-274. J.B.Lippincott, Philadelphia, USA. P.A. Pizzo, D.G. Poplack (Eds.).
7. Murry D.J., Crom W.R., Reddick W.E., Bhargava R., Evans W.E. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995, 23:1110-1116.
8. Pieters R., Schrappe M., De L.P., Hann I., De R.G., Felice M., et al. A treatment protocol for infants younger than 1year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007, 370:240-250.
9. van der Linden M.H., Valsecchi M.G., De L.P., Moricke A., Janka G., Leblanc T.M., et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 2009, 114:3764-3768.
10. Hempel G., Relling M.V., De R.G., Stary J., De L.P., Valsecchi M.G., et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 2010, 54:355-360.
11. Adamson P.C. It's not easy being small. Pediatr Blood Cancer 2010, 54:341-343.
12. Breitkreuz J., Buckham J., Fischer R., Postges R., Boos J. Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. Paed Perinat Drug Ther 2007, 8:31-39.
13. Huang N.N., High R.H. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 1953, 42:657-658.
14. Agunod M., Yamaguchi N., Lopez R., Luhby A.L., Glass G.B. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969, 14:400-414.
15. Kearns G.L., Bdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
16. Gupta M., Brans Y.W. Gastric retention in neonates. Pediatrics 1978, 62:26-29.
17. Ittmann P.I., Amarnath R., Berseth C.L. Maturation of antroduodenal motor activity in preterm and term infants. Dig Dis Sci 1992, 37:14-19.
18. Huang C.T., Rodriguez J.T., Woodward W.E., Nichols B.L. Comparison of patterns of fecal bile acid and neutral sterol between children and adults. Am J Clin Nutr 1976, 29:1196-1203.
19. Poley J.R., Dower J.C., Owen C.A., Stickler G.B. Bile acids in infants and children. J Lab Clin Med 1964, 63:838-846.
20. Weaver L.T., Austin S., Cole T.J. Small intestinal length: a factor essential for gut adaptation. Gut 1991, 32:1321-1323.
21. Johnson T.N., Rostami-Hodjegan A., Tucker G.T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006, 45:931-956.
22. Linday L., Dobkin J.F., Wang T.C., Butler V.P., Saha J.R., Lindenbaum J. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987, 79:544-548.
23. Stahlberg M.R., Hietanen E., Maki M. Mucosal biotransformation rates in the small intestine of children. Gut 1988, 29:1058-1063.
24. Fakhoury M., Litalien C., Medard Y., Cave H., Ezzahir N., Peuchmaur M., et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005, 33:1603-1607.
25. Johnson T.N., Tanner M.S., Taylor C.J., Tucker G.T. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001, 51:451-460.
26. Reed M.D., Besunder J.B. Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am 1989, 36:1053-1074.
27. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl 1983, 305:7-11.
28. Hines R.N. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008, 118:250-267.
29. Blanco J.G., Harrison P.L., Evans W.E., Relling M.V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000, 28:379-382.
30. Takahashi H., Ishikawa S., Nomoto S., Nishigaki Y., Ando F., Kashima T., et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000, 68:541-555.
31. Miyagi S.J., Collier A.C. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 2007, 35:1587-1592.
32. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
33. Hines R.N., McCarver D.G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002, 300:355-360.
34. McCarver D.G., Hines R.N. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002, 300:361-366.
35. McLemore T.L., Adelberg S., Liu M.C., McMahon N.A., Yu S.J., Hubbard W.C., et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990, 82:1333-1339.
36. Goria-Gatti L., Iannone A., Tomasi A., Poli G., Albano E. In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis 1992, 13:799-805.
37. Sonnier M., Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998, 251:893-898.
38. Blake M.J., Abdel-Rahman S.M., Pearce R.E., Leeder J.S., Kearns G.L. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006, 60:717-723.
39. Le Guennec J.C., Billon B. Delay in caffeine elimination in breast-fed infants. Pediatrics 1987, 79:264-268.
40. van Schaik R.H. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005, 23:513-522.
41. Scripture C.D., Sparreboom A., Figg W.D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005, 6:780-789.
42. Kawashiro T., Yamashita K., Zhao X.J., Koyama E., Tani M., Chiba K., et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998, 286:1294-1300.
43. Bieche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., et al. I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007, 17:731-742.
44. Hakkola J., Pasanen M., Pelkonen O., Hukkanen J., Evisalmi S., Anttila S., et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 1997, 18:391-397.
45. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000, 60:5074-5079.
46. Raunio H., Valtonen J., Honkakoski P., Lang M.A., Stahlberg M., Kairaluoma M.A., et al. Immunochemical detection of human liver cytochrome P450 forms related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol 1990, 40:2503-2509.
47. Gu J., Su T., Chen Y., Zhang Q.Y., Ding X. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 2000, 165:158-162.
48. Crespi C.L., Penman B.W., Leakey J.A., Arlotto M.P., Stark A., Parkinson A., et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 1990, 11:1293-1300.
49. Ikeda K., Yoshisue K., Matsushima E., Nagayama S., Kobayashi K., Tyson C.A., et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000, 6:4409-4415.
50. de Jonge M.E., Huitema A.D., Rodenhuis S., Beijnen J.H. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005, 44:1135-1164.
51. Croom E.L., Stevens J.C., Hines R.N., Wallace A.D., Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009, 78:184-190.
52. Xie H.J., Yasar U., Lundgren S., Griskevicius L., Terelius Y., Hassan M., et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003, 3:53-61.
53. Huang Z., Roy P., Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000, 59:961-972.
54. Jacobson P.A., Green K., Birnbaum A., Remmel R.P. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002, 49:461-467.
55. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003, 307:906-922.
56. Wrighton S.A., Brian W.R., Sari M.A., Iwasaki M., Guengerich F.P., Raucy J.L., et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990, 38:207-213.
57. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270:414-423.
58. Koukouritaki S.B., Manro J.R., Marsh S.A., Stevens J.C., Rettie A.E., McCarver D.G., et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004, 308:965-974.
59. Leff R.D., Fischer L.J., Roberts R.J. Phenytoin metabolism in infants following intravenous and oral administration. Dev Pharmacol Ther 1986, 9:217-223.
60. Andrew M., Marzinotto V., Brooker L.A., Adams M., Ginsberg J., Freedom R., et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994, 71:265-269.
61. Griskevicius L., Yasar U., Sandberg M., Hidestrand M., Eliasson E., Tybring G., et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003, 59:103-109.
62. Relling M.V., Evans W.E., Fonne-Pfister R., Meyer U.A. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 1989, 49:68-71.
63. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11:597-607.
64. Treluyer J.M., Jacqz-Aigrain E., Alvarez F., Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991, 202:583-588.
65. Endrizzi K., Fischer J., Klein K., Schwab M., Nussler A., Neuhaus P., et al. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2002, 300:121-131.
66. Gaedigk A., Gaedigk R., Leeder J.S. CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein?. Biochem Biophys Res Commun 2005, 336:1241-1250.
67. Vieira I., Pasanen M., Raunio H., Cresteil T. Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol Toxicol 1998, 83:183-187.
68. Vieira I., Sonnier M., Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996, 238:476-483.
69. Johnsrud E.K., Koukouritaki S.B., Divakaran K., Brunengraber L.L., Hines R.N., McCarver D.G. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003, 307:402-407.
70. Li A.P., Kaminski D.L., Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995, 104:1-8.
71. Ozdemir V., Kalow W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000, 10:373-388.
72. Stevens J.C., Hines R.N., Gu C., Koukouritaki S.B., Manro J.R., Tandler P.J., et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003, 307:573-582.
73. Yang H.Y., Lee Q.P., Rettie A.E., Juchau M.R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 1994, 46:922-928.
74. Chen H., Fantel A.G., Juchau M.R. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos 2000, 28:1051-1057.
75. Schuetz J.D., Beach D.L., Guzelian P.S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994, 4:11-20.
76. Hakkola J., Raunio H., Purkunen R., Saarikoski S., Vahakangas K., Pelkonen O., et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001, 80:193-201.
77. de Wildt S.N., Kearns G.L., Leeder J.S., van den Anker J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999, 37:485-505.
78. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
79. Hustert E., Haberl M., Burk O., Wolbold R., He Y.Q., Klein K., et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11:773-779.
80. Lacroix D., Sonnier M., Moncion A., Cheron G., Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997, 247:625-634.
81. Shou M., Martinet M., Korzekwa K.R., Krausz K.W., Gonzalez F.J., Gelboin H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998, 8:391-401.
82. Kishi S., Yang W., Boureau B., Morand S., Das S., Chen P., et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004, 103:67-72.
83. Krueger S.K., Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005, 106:357-387.
84. Koukouritaki S.B., Simpson P., Yeung C.K., Rettie A.E., Hines R.N. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002, 51:236-243.
85. Smith M., Hopkinson D.A., Harris H. Developmental changes and polymorphism in human alcohol dehydrogenase. Ann Hum Genet 1971, 34:251-271.
86. Smith M., Hopkinson D.A., Harris H. Alcohol dehydrogenase isozymes in adult human stomach and liver: evidence for activity of the ADH 3 locus. Ann Hum Genet 1972, 35:243-253.
87. Estonius M., Svensson S., Hoog J.O. Alcohol dehydrogenase in human tissues: localisation of transcripts coding for five classes of the enzyme. FEBS Lett 1996, 397:338-342.
88. Alnouti Y., Klaassen C.D. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. Toxicol Sci 2008, 101:51-64.
89. Tsukamoto N., Chen J., Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol Dis 1998, 24:231-238.
90. Pacifici G.M., Romiti P., Giuliani L., Rane A. Thiopurine methyltransferase in humans: development and tissue distribution. Dev Pharmacol Ther 1991, 17:16-23.
91. McLeod H.L., Krynetski E.Y., Wilimas J.A., Evans W.E. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995, 5:281-286.
92. Tayama Y., Miyake K., Sugihara K., Kitamura S., Kobayashi M., Morita S., et al. Developmental changes of aldehyde oxidase activity in young Japanese children. Clin Pharmacol Ther 2007, 81:567-572.
93. Nebert D.W., Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics 2004, 1:460-464.
94. Hayes J.D., Pulford D.J., Ellis E.M., McLeod R., James R.F., Seidegard J., et al. Regulation of rat glutathione S-transferase A5 by cancer chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1. Chem Biol Interact 1998, 111-112:51-67.
95. Pacifici G.M., Rane A. Epoxide hydrolase in human fetal liver. Pharmacology 1983, 26:241-248.
96. Strange R.C., Howie A.F., Hume R., Matharoo B., Bell J., Hiley C., et al. The development expression of alpha-, mu- and pi-class glutathione S-transferases in human liver. Biochim Biophys Acta 1989, 993:186-190.
97. Pacifici G.M., Franchi M., Giuliani L., Rane A. Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus. Dev Pharmacol Ther 1989, 14:108-114.
98. Duanmu Z., Weckle A., Koukouritaki S.B., Hines R.N., Falany J.L., Falany C.N., et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre- and postnatal human liver. J Pharmacol Exp Ther 2006, 316:1310-1317.
99. Richard K., Hume R., Kaptein E., Stanley E.L., Visser T.J., Coughtrie M.W. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab 2001, 86:2734-2742.
100. Stanley E.L., Hume R., Coughtrie M.W. Expression profiling of human fetal cytosolic sulfotransferases involved in steroid and thyroid hormone metabolism and in detoxification. Mol Cell Endocrinol 2005, 240:32-42.
101. Cappiello M., Giuliani L., Rane A., Pacifici G.M. Dopamine sulphotransferase is better developed than p-nitrophenol sulphotransferase in the human fetus. Dev Pharmacol Ther 1991, 16:83-88.
102. Williams J.A., Hyland R., Jones B.C., Smith D.A., Hurst S., Goosen T.C., et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004, 32:1201-1208.
103. Burchell B., Coughtrie M., Jackson M., Harding D., Fournel-Gigleux S., Leakey J., et al. Development of human liver UDP-glucuronosyltransferases. Dev Pharmacol Ther 1989, 13:70-77.
104. de Wildt S.N., Kearns G.L., Leeder J.S., Van den Anker J.N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999, 36:439-452.
105. Strassburg C.P., Strassburg A., Kneip S., Barut A., Tukey R.H., Rodeck B., et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002, 50:259-265.
106. Zaya M.J., Hines R.N., Stevens J.C. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 2006, 34:2097-2101.
107. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002, 2:43-47.
108. Pacifici G.M., Bencini C., Rane A. Acetyltransferase in humans: development and tissue distribution. Pharmacology 1986, 32:283-291.
109. Hook J.B., Hewitt W.R. Development of mechanisms for drug excretion. Am J Med 1977, 62:497-506.
110. Alcorn J., McNamara P.J. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003, 55:667-686.
111. Siegel S.E., Moran R.G. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol 1981, 3:287-296.
112. Pichard L., Fabre I., Daujat M., Domergue J., Joyeux H., Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992, 41:1047-1055.
113. Gouyette A., Hartmann O., Pico J.L. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 1986, 16:184-189.
114. Morris M.E., Griener J.C., Msall M.E. N-acetylator variability in Down's syndrome: characterization with caffeine. Clin Pharmacol Ther 1989, 46:359-366.
115. Yule S.M., Boddy A.V., Cole M., Price L., Wyllie R., Tasso M.J., et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996, 41:13-19.
116. Yule S.M., Boddy A.V., Cole M., Price L., Wyllie R., Tasso M.J., et al. Cyclophosphamide metabolism in children. Cancer Res 1995, 55:803-809.
117. Yule S.M., Price L., McMahon A.D., Pearson A.D., Boddy A.V. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 2004, 10:455-460.
118. Carrier O., Pons G., Rey E., Richard M.O., Moran C., Badoual J., et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 1988, 44:145-151.
119. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007, 116:496-526.
120. Timm R., Kaiser R., Lotsch J., Heider U., Sezer O., Weisz K., et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005, 5:365-373.
121. DeMichele A., Aplenc R., Botbyl J., Colligan T., Wray L., Klein-Cabral M., et al. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005, 23:5552-5559.
122. Mahmood B., Daood M.J., Hart C., Hansen T.W., Watchko J.F. Ontogeny of P-glycoprotein in mouse intestine, liver, and kidney. J Investig Med 2001, 49:250-257.
123. Johnson D.R., Guo G.L., Klaassen C.D. Expression of rat Multidrug Resistance Protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. Toxicology 2002, 178:209-219.
124. Schiengold M., Schwantes L., Schwartsmann G., Chies J.A., Nardi N.B. Multidrug resistance gene expression during the murine ontogeny. Mech Ageing Dev 2001, 122:255-270.
125. Kumarakulasingham M., Rooney P.H., Dundas S.R., Telfer C., Melvin W.T., Curran S., et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res 2005, 11:3758-3765.
126. Dhaini H.R., Thomas D.G., Giordano T.J., Johnson T.D., Biermann J.S., Leu K., et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003, 21:2481-2485.
127. McFadyen M.C., Melvin W.T., Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004, 3:363-371.
128. Juma F.D., Rogers H.J., Trounce J.R. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 1979, 8:209-217.
129. D'Incalci M., Bolis G., Facchinetti T., Mangioni C., Morasca L., Morazzoni P., et al. Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer 1979, 15:7-10.
130. Schmidt R., Baumann F., Knupfer H., Brauckhoff M., Horn L.C., Schonfelder M., et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 2004, 90:911-916.
131. Juma F.D., Rogers H.J., Trounce J.R. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 1980, 10:327-335.
132. Bruggemann S.K., Kisro J., Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 1997, 57:2676-2680.
133. Lind M.J., McGown A.T., Hadfield J.A., Thatcher N., Crowther D., Fox B.W. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989, 38:1835-1840.
134. Dockham P.A., Lee M.O., Sladek N.E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992, 43:2453-2469.
135. Ren S., Kalhorn T.F., Slattery J.T. Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Drug Metab Dispos 1999, 27:133-137.
136. Tew K.D., Colvin O.M., Jones R.B. Clinical and high-dose alkylating agents. Cancer Chemotherapy & Biotherapy 2010, 281-309. Lippincott Williams &Wilkins, Philadelphia, US. B. Chabner, D.L. Longo (Eds.).
137. Mouridsen H.T., Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh) 1975, 36:409-414.
138. Groninger E., Proost J.H., de Graaf S.S. Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol 2004, 52:173-197.
139. Tasso M.J., Boddy A.V., Price L., Wyllie R.A., Pearson A.D., Idle J.R. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992, 30:207-211.
140. Yule S.M., Hide T.A., Cranney M., Simpson E., Barrett A. Low grade astrocytomas in the West of Scotland 1987-96: treatment, outcome, and cognitive functioning. Arch Dis Child 2001, 84:61-64.
141. McCune J.S., Salinger D.H., Vicini P., Oglesby C., Blough D.K., Park J.R. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol 2009, 49:88-102.
142. Creaven P.J., Allen L.M., Alford D.A., Cohen M.H. Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 1974, 16:77-86.
143. Kerbusch T., de K.J., Mathjt R.A., Beijne J.H. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinet 2001, 40:615-625.
144. Brade W.P., Herdrich K., Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985, 12:1-47.
145. Norpoth K. Studies on the metabolism of isopnosphamide (NSC-109724) in man. Cancer Treat Rep 1976, 60:437-443.
146. Chang T.K., Weber G.F., Crespi C.L., Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993, 53:5629-5637.
147. Kaijser G.P., de K.J., Bult A., Underberg W.J., Beijnen J.H. Pharmacokinetics of ifosfamide and some metabolites in children. Anticancer Res 1998, 18:1941-1949.
148. Kerbusch T., de K.J., Keizer H.J., van Putten J.W., Groen H.J., Jansen R.L., et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001, 40:41-62.
149. Boddy A.V., Cole M., Pearson A.D., Idle J.R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995, 36:53-60.
150. Prasad V.K., Corlett S.A., Abaasi K., Heney D., Lewis I., Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother Pharmacol 1994, 34:447-449.
151. Corlett S.A., Parker D., Chrystyn H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol 1995, 39:452-455.
152. Antman K.H., Ryan L., Elias A., Sherman D., Grier H.E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989, 7:126-131.
153. Boddy A.V., Yule S.M., Wyllie R., Price L., Pearson A.D., Idle J.R. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995, 31A:785-790.
154. Boddy A.V., Yule S.M., Wyllie R., Price L., Pearson A.D., Idle J.R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 1993, 53:3758-3764.
155. Friedman H.S., Averbuch S.D., Kurtzberg J. Nonclassical Agents. Cancer Chemotherapy & Biotherapy 2010, 310-331. Lippincott Williams &Wilkins, Philadelphia, US. B. Chabner, D.L. Longo (Eds.).
156. 6-methylguanine and methylphosphotriesters to the cytotoxicity of alkylating agents in mammalian cells. Carcinogenesis 1988, 9:1587-1593.
157. Lunn J.M., Harris A.L. Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide. Br J Cancer 1988, 57:54-58.
158. Panetta J.C., Kirstein M.N., Gajjar A., Nair G., Fouladi M., Heideman R.L., et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 2003, 52:435-441.
159. Sardi I., Cetica V., Massimino M., Buccoliero A.M., Giunti L., Genitori L., et al. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Oncol Rep 2009, 22:773-779.
160. de Jonge M.E., Huitema A.D., Rodenhuis S., Beijnen J.H. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn 2004, 31:135-156.
161. Maanen M.J., Smeets C.J., Beijnen J.H. Chemistry, pharmacology and pharmacokinetics of N, N', N'-triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev 2000, 26:257-268.
162. Tew K.D., Colvin O.M., Jones R.B. Clinical and high-dose alkylating agents. Cancer Chemotherapy & Biotherapy 2010, 281-309. Lippincott Williams &Wilkins, Philadelphia, US. B. Chabner, D.L. Longo (Eds.).
163. Kletzel M., Kearns G.L., Wells T.G., Thompson H.C. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation. Bone marrow transplant 1992, 10:171-175.
164. Kohn K.W., Spears C.L., Doty P. Inter-strand crosslinking of DNA by nitrogen mustard. J Mol Biol 1966, 19:266-288.
165. Ludlum D.B., Kramer B.S., Wang J., Fenselau C. Reaction of 1,3-bis(2-chloroethyl)-1-nitrosourea with synthetic polynucleotides. Biochemistry 1975, 14:5480-5485.
166. May H.E., Kohlhepp S.J., Boose R.B., Reed D.J. Synthesis and identification of products derived from the metabolism of the carcinostatic 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea by rat liver microsomes. Cancer Res 1979, 39:762-772.
167. Kramer R.A. Cytochrome P-450-dependent formation of alkylating metabolites of the 2-chloroethylnitrosoureas MeCCNU and CCNU. Biochem Pharmacol 1989, 38:3185-3192.
168. Wheeler G.P., Johnston T.P., Bowdon B.J., McCaleb G.S., Hill D.L., Montgomery J.A. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol 1977, 26:2331-2336.
169. Kastrissios H., Chao N.J., Blaschke T.F. Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemother Pharmacol 1996, 38:425-430.
170. Begleiter A., Mowat M., Israels L.G., Johnston J.B. Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 1996, 23:187-201.
171. Zwaveling J., Press R.R., Bredius R.G., van Derstraaten T.R., den H.J., Bartelink I.H., et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008, 30:504-510.
172. Bartelink I.H., Bredius R.G., Belitser S.V., Suttorp M.M., Bierings M., Knibbe C.A., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:231-241.
173. Schechter T., Finkelstein Y., Doyle J., Verjee Z., Moretti M., Koren G., et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:307-314.
174. Dalle J.H., Wall D., Theoret Y., Duval M., Shaw L., Larocque D., et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003, 32:647-651.
175. Bostrom B., Enockson K., Johnson A., Bruns A., Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003, 7(Suppl 3):12-18.
176. Hassan M., Fasth A., Gerritsen B., Haraldsson A., Syruckova Z., van den Berg H., et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996, 18:843-850.
177. Vassal G., Gouyette A., Hartmann O., Pico J.L., Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989, 24:386-390.
178. Nakamura H., Sato T., Okada K., Miura G., Ariyoshi N., Nakazawa K., et al. Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Ther Drug Monit 2008, 30:75-83.
179. Vassal G., Michel G., Esperou H., Gentet J.C., Valteau-Couanet D., Doz F., et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008, 61:113-123.
180. Gibbs J.P., Liacouras C.A., Baldassano R.N., Slattery J.T. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999, 27:1466-1469.
181. Wall D.A., Chan K.W., Nieder M.L., Hayashi R.J., Yeager A.M., Kadota R., et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010, 54:291-298.
182. Tattersall M.H., Jarman M., Newlands E.S., Holyhead L., Milstead R.A., Weinberg A. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 1978, 14:507-513.
183. Davis T.P., Peng Y.M., Goodman G.E., Alberts D.S. HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. J Chromatogr Sci 1982, 20:511-516.
184. Taha I.A., Ahmad R.A., Rogers D.W., Pritchard J., Rogers H.J. Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 1983, 10:212-216.
185. Alberts D.S., Chang S.Y., Chen H.S., Moon T.E., Evans T.L., Furner R.L., et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979, 26:73-80.
186. Tricot G., Alberts D.S., Johnson C., Roe D.J., Dorr R.T., Bracy D., et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947-952.
187. Nath C.E., Shaw P.J., Montgomery K., Earl J.W. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007, 64:151-164.
188. Nath C.E., Shaw P.J., Montgomery K., Earl J.W. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 2005, 59:314-324.
189. Ueda T., Matsuyama S., Yamauchi T., Kishi S., Fukushima T., Tsutani H., et al. Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies. Adv Exp Med Biol 1998, 431:647-651.
190. Koehl U., Hollatz G., Rohrbach E., Visschedyk K., Cinatl J., Kornhuber B., et al. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. Cancer Chemother Pharmacol 2007, 60:467-477.
191. Capizzi R.L., Yang J.L., Cheng E., Bjornsson T., Sahasrabudhe D., Tan R.S., et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983, 1:763-771.
192. Avramis V.I., Weinberg K.I., Sato J.K., Lenarsky C., Willoughby M.L., Coates T.D., et al. Pharmacology studies of 1-beta-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res 1989, 49:241-247.
193. van Prooijen H.C., Dekker A.W., Punt K. The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 1984, 57:291-299.
194. Periclou A.P., Avramis V.I. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996, 39:42-50.
195. Stam R.W., den Boer M.L., Meijerink J.P., Ebus M.E., Peters G.J., Noordhuis P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003, 101:1270-1276.
196. Avramis V.I., Wiersma S., Krailo M.D., Ramilo-Torno L.V., Sharpe A., Liu-Mares W., et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998, 4:45-52.
197. McLeod H.L., Relling M.V., Crom W.R., Silverstein K., Groom S., Rodman J.H., et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992, 18:S23-S29.
198. Lund B., Kristjansen P.E., Hansen H.H. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993, 19:45-55.
199. Kaye S.B. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994, 12:1527-1531.
200. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 1990, 50:4417-4422.
201. Gandhi V., Legha J., Chen F., Hertel L.W., Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 1996, 56:4453-4459.
202. Iwasaki H., Huang P., Keating M.J., Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997, 90:270-278.
203. Steinherz P.G., Seibel N.L., Ames M.M., Avramis V.I., Krailo M.D., Liu-Mares W., et al. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group. Leuk Lymphoma 2002, 43:1945-1950.
204. Reid J.M., Qu W., Safgren S.L., Ames M.M., Krailo M.D., Seibel N.L., et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004, 22:2445-2451.
205. Nieto Y., Aldaz A., Rifon J., Perez-Calvo J., Zafra A., Zufia L., et al. Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Biol Blood Marrow Transplant 2007, 13:1324-1337.
206. Chu E., Drake J.C., Boarman D., Baram J., Allegra C.J. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem 1990, 265:8470-8478.
207. Lyons S.D., Sant M.E., Christopherson R.I. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia. J Biol Chem 1990, 265:11377-11381.
208. Borsi J.D., Sagen E., Romslo I., Slordal L., Moe P.J. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1990, 27:164-167.
209. Whitehead V.M., Payment C., Cooley L., Lauer S.J., Mahoney D.H., Shuster J.J., et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2001, 15:1081-1088.
210. Graham M.L., Shuster J.J., Kamen B.A., Land V.J., Borowitz M.J., Camitta B., et al. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. Clin Cancer Res 1996, 2:331-337.
211. Paal K., Horvath J., Csaki C., Ferencz T., Schuler D., Borsi J.D. Effect of etoposide on the pharmacokinetics of methotrexate in vivo. Anticancer Drugs 1998, 9:765-772.
212. Thompson P.A., Murry D.J., Rosner G.L., Lunagomez S., Blaney S.M., Berg S.L., et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007, 59:847-853.
213. Murry D.J., Synold T.W., Pui C.H., Rodman J.H. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy 1995, 15:144-149.
214. Donelli M.G., Zucchetti M., Robatto A., Perlangeli V., D'Incalci M., Masera G., et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995, 24:154-159.
215. Lonnerholm G., Valsecchi M.G., De L.P., Schrappe M., Hovi L., Campbell M., et al. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2009, 52:596-601.
216. Ramakers-van Woerden N.L., Pieters R., Rots M.G., van Zantwijk C.H., Noordhuis P., Beverloo H.B., et al. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. Leukemia 2002, 16:949-951.
217. Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004, 10:4276s-4280s.
218. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
219. Mendelsohn L.G., Shih C., Chen V.J., Habeck L.L., Gates S.B., Shackelford K.A. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999, 26:42-47.
220. Zhao R., Babani S., Gao F., Liu L., Goldman I.D. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000, 6:3687-3695.
221. Malempati S., Nicholson H.S., Reid J.M., Blaney S.M., Ingle A.M., Krailo M., et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 2007, 25:1505-1511.
222. Kato Y., Matsushita T., Uchida H., Egi S., Yokoyama T., Mohri K. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism. Eur J Clin Pharmacol 1992, 42:619-622.
223. Zimm S., Collins J.M., Riccardi R., O'Neill D., Narang P.K., Chabner B., et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med 1983, 308:1005-1009.
224. Zimm S., Collins J.M., O'Neill D., Chabner B.A., Poplack D.G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983, 34:810-817.
225. Kato Y., Matsushita T., Chiba K., Hijiya N., Yokoyama T., Ishizaki T. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. J Pediatr 1991, 119:311-316.
226. Tidd D.M., Paterson A.R. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974, 34:733-737.
227. Lennard L., Welch J., Lilleyman J.S. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?. Br J Cancer 1995, 72:1004-1006.
228. Wang L., Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006, 25:1629-1638.
229. Krynetski E.Y., Tai H.L., Yates C.R., Fessing M.Y., Loennechen T., Schuetz J.D., et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6:279-290.
230. Lennard L., Van Loon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989, 46:149-154.
231. Schmiegelow K., Forestier E., Kristinsson J., Soderhall S., Vettenranta K., Weinshilboum R., et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009, 23:557-564.
232. Zimm S., Ettinger L.J., Holcenberg J.S., Kamen B.A., Vietti T.J., Belasco J., et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985, 45:1869-1873.
233. Balis F.M., Holcenberg J.S., Poplack D.G., Ge J., Sather H.N., Murphy R.F., et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 1998, 92:3569-3577.
234. Lowe E.S., Kitchen B.J., Erdmann G., Stork L.C., Bostrom B.C., Hutchinson R., et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. Cancer Chemother Pharmacol 2001, 47:199-205.
235. Adamson P.C., Poplack D.G., Balis F.M. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994, 18:805-810.
236. Pieters R., Huismans D.R., Leyva A., Veerman A.J. Sensitivity to purine analogues in childhood leukemia assessed by the automated MTT-assay. Adv Exp Med Biol 1989, 253A:447-454.
237. Erb N., Harms D.O., Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998, 42:266-272.
238. Stork L.C., Matloub Y., Broxson E., La M., Yanofsky R., Sather H., et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010, 115:2740-2748.
239. Josefine P., Britt-Marie F., Curt P., Henrik H., Marit H., Jukka K., et al. Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Anticancer Drugs 2009, 20:7-14.
240. Keyomarsi K., Moran R.G. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986, 46:5229-5235.
241. Patel R., Newman E.M., Villacorte D.G., Sato J.K., Reaman G.H., Finklestein J.Z., et al. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. Cancer Res 1991, 51:4871-4875.
242. Pettitt A.R. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2003, 121:692-702.
243. Malspeis L., Grever M.R., Staubus A.E., Young D. Pharmacokinetics of 2-F-ara-A (9-beta-d-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990, 17:18-32.
244. Sandoval A., Consoli U., Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996, 2:1731-1741.
245. Gandhi V., Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002, 41:93-103.
246. Avramis V.I., Champagne J., Sato J., Krailo M., Ettinger L.J., Poplack D.G., et al. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 1990, 50:7226-7231.
247. Plunkett W., Saunders P.P. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 1991, 49:239-268.
248. Chunduru S.K., Appleman J.R., Blakley R.L. Activity of human DNA polymerases alpha and beta with 2-chloro-2'-deoxyadenosine 5'-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 1993, 302:19-30.
249. Hande K.R. Purin Antimetabolites. Cancer Chemotherapy & Biotherapy 2010, 212-236. Lippincott Williams &Wilkins, Philadelphia, US. B. Chabner, D.L. Longo (Eds.).
250. Kearns C.M., Blakley R.L., Santana V.M., Crom W.R. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994, 54:1235-1239.
251. Crews K.R., Gandhi V., Srivastava D.K., Razzouk B.I., Tong X., Behm F.G., et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 2002, 20:4217-4224.
252. Watanabe K., Williams E.F., Law J.S., West W.L. Effects of vinca alkaloids on calcium-calmodulin regulated cyclic adenosine 3',5'-monophosphatase phosphodiesterase activity from brain. Biochem Pharmacol 1981, 30:335-340.
253. Wilson L. Microtubules as drug receptors: pharmacological properties of microtubule protein. Ann NY Acad Sci 1975, 253:213-231.
254. Crossin K.L., Carney D.H. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 1981, 27:341-350.
255. Jordan M.A., Himes R.H., Wilson L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res 1985, 45:2741-2747.
256. Bourgeois H., Vermorken J., Dark G., Jones A., Fumoleau P., Stupp R., et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 2007, 60:407-413.
257. Bugat R., Variol P., Roche H., Fumoleau P., Robinet G., Senac I. The effects of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 2002, 50:285-290.
258. Johansen M., Kuttesch J., Bleyer W.A., Krailo M., Ames M., Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. Clin Cancer Res 2006, 12:516-522.
259. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001, 12:1643-1649.
260. Wargin W.A., Lucas V.S. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 1994, 21:21-27.
261. Zhou-Pan X.R., Seree E., Zhou X.J., Placidi M., Maurel P., Barra Y., et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993, 53:5121-5126.
262. Yao D., Ding S., Burchell B., Wolf C.R., Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000, 294:387-395.
263. Groninger E., Meeuwsen-de B.T., Koopmans P., Uges D., Sluiter W., Veerman A., et al. Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. Pediatr Res 2002, 52:113-118.
264. Crom W.R., de Graaf S.S., Synold T., Uges D.R., Bloemhof H., Rivera G., et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994, 125:642-649.
265. Gidding C.E., Meeuwsen-de Boer G.J., Koopmans P., Uges D.R., Kamps W.A., de Graaf S.S. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999, 44:203-209.
266. Plasschaert S.L., Groninger E., Boezen M., Kema I., de Vries E.G., Uges D., et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004, 76:220-229.
267. Groninger E., Meeuwsen-de B.T., Koopmans P., Uges D., Sluiter W., Veerman A., et al. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). Eur J Cancer 2005, 41:98-103.
268. Lonnerholm G., Frost B.M., Abrahamsson J., Behrendtz M., Castor A., Forestier E., et al. Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. Br J Haematol 2008, 142:616-621.
269. Frost B.M., Lonnerholm G., Koopmans P., Abrahamsson J., Behrendtz M., Castor A., et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 2003, 92:551-557.
270. Henningsson A., Marsh S., Loos W.J., Karlsson M.O., Garsa A., Mross K., et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005, 11:8097-8104.
271. Hurwitz C.A., Relling M.V., Weitman S.D., Ravindranath Y., Vietti T.J., Strother D.R., et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1993, 11:2324-2329.
272. Lesser G.J., Grossman S.A., Eller S., Rowinsky E.K. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol 1995, 37:173-178.
273. Hayashi R.J., Blaney S., Sullivan J., Weitman S., Vietti T., Bernstein M.L. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 2003, 25:539-542.
274. Woo M.H., Relling M.V., Sonnichsen D.S., Rivera G.K., Pratt C.B., Pui C.H., et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999, 5:543-549.
275. Doz F., Gentet J.C., Pein F., Frappaz D., Chastagner P., Moretti S., et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 2001, 84:604-610.
276. Horton T.M., Ames M.M., Reid J.M., Krailo M.D., Pendergrass T., Mosher R., et al. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer 2008, 50:788-792.
277. van Schaik R.H. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008, 11:77-98.
278. Franklin J.L., Seibel N.L., Krailo M., Fu C., Adamson P.C., Reaman G. Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report. Pediatr Blood Cancer 2008, 50:533-536.
279. Seibel N.L., Blaney S.M., O'Brien M., Krailo M., Hutchinson R., Mosher R.B., et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 1999, 5:733-737.
280. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002, 3:430-440.
281. Pommier Y., Goldwasser F. Topoisomerase II Inhibitors. Cancer Chemotherapy & Biotherapy 2006, 451-475. Lippincott Williams & Wilkins, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
282. Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994, 45:352-358.
283. Palle J., Britt-Marie F., Goran G., Marit H., Jukka K., Eva L., et al. Etoposide pharmacokinetics in children treated for acute myeloid leukemia. Anticancer Drugs 2006, 17:1087-1094.
284. Boos J., Real E., Schulze W., Wolff J., Euting T., Jurgens H. Investigation of the variability of etoposide pharmacokinetics in children. Int J Clin Pharmacol Ther Toxicol 1992, 30:495-497.
285. Kato Y., Nishimura S., Sakura N., Ueda K. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int 2003, 45:74-79.
286. Eksborg S., Soderhall S., Frostvik-Stolt M., Lindberg A., Liliemark E. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children. Anticancer Drugs 2000, 11:237-241.
287. Veal G.J., Cole M., Errington J., Pearson A.D., Gerrard M., Whyman G., et al. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol 2010, 65:1057-1066.
288. Lowis S.P., Pearson A.D., Newell D.R., Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 1993, 53:4881-4889.
289. Creaven P.J. The clinical pharmacology of VM26 and VP16-213. A brief overview. Cancer Chemother Pharmacol 1982, 7:133-140.
290. Evans W.E., Sinkule J.A., Crom W.R., Dow L., Look A.T., Rivera G. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemother Pharmacol 1982, 7:147-150.
291. Sinkule J.A., Stewart C.F., Crom W.R., Melton E.T., Dahl G.V., Evans W.E. Teniposide (VM26) disposition in children with leukemia. Cancer Res 1984, 44:1235-1237.
292. D'Incalci M., Farina P., Sessa C., Mangioni C., Conter V., Masera G., et al. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 1982, 7:141-145.
293. Herben V.M., ten Bokkel Huinink W.W., Beijnen J.H. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996, 31:85-102.
294. Grochow L.B., Rowinsky E.K., Johnson R., Ludeman S., Kaufmann S.H., McCabe F.L., et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992, 20:706-713.
295. Furman W.L., Baker S.D., Pratt C.B., Rivera G.K., Evans W.E., Stewart C.F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996, 14:1504-1511.
296. Blaney S.M., Phillips P.C., Packer R.J., Heideman R.L., Berg S.L., Adamson P.C., et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996, 78:527-531.
297. Rosing H., Herben V.M., van Gortel-van Zomeren D.M., Hop E., Kettenes-van den Bosch J.J., ten Bokkel Huinink W.W., et al. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 1997, 39:498-504.
298. Rosing H., van Zomeren D.M., Doyle E., Bult A., Beijnen J.H. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs 1998, 9:587-592.
299. Herben V.M., Schoemaker E., Rosing H., van Zomeren D.M., ten Bokkel Huinink W.W., Dubbelman R., et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002, 50:59-64.
300. Dennis M.J., Beijnen J.H., Grochow L.B., van Warmerdam L.J. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997, 24:S5.
301. Wagner S., Erdlenbruch B., Langler A., Gnekow A., Kuhl J., Albani M., et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer 2004, 100:1750-1757.
302. Athale U.H., Stewart C., Kuttesch J.F., Moghrabi A., Meyer W., Pratt C., et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002, 20:88-95.
303. Blaney S.M., Balis F.M., Cole D.E., Craig C., Reid J.M., Ames M.M., et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993, 53:1032-1036.
304. Daw N.C., Santana V.M., Iacono L.C., Furman W.L., Hawkins D.R., Houghton P.J., et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 2004, 22:829-837.
305. Frangoul H., Ames M.M., Mosher R.B., Reid J.M., Krailo M.D., Seibel N.L., et al. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res 1999, 5:3956-3962.
306. Pratt C.B., Stewart C., Santana V.M., Bowman L., Furman W., Ochs J., et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994, 12:539-543.
307. Santana V.M., Furman W.L., Billups C.A., Hoffer F., Davidoff A.M., Houghton P.J., et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005, 23:4039-4047.
308. Stewart C.F., Baker S.D., Heideman R.L., Jones D., Crom W.R., Pratt C.B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994, 12:1946-1954.
309. Tubergen D.G., Stewart C.F., Pratt C.B., Zamboni W.C., Winick N., Santana V.M., et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 1996, 18:352-361.
310. Stewart C.F., Iacono L.C., Chintagumpala M., Kellie S.J., Ashley D., Zamboni W.C., et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004, 22:3357-3365.
311. Panetta J.C., Schaiquevich P., Santana V.M., Stewart C.F. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 2008, 14:318-325.
312. Schaiquevich P., Panetta J.C., Iacono L.C., Freeman B.B., Santana V.M., Gajjar A., et al. Population pharmacokinetic analysis of topotecan in pediatric cancer patients. Clin Cancer Res 2007, 13:6703-6711.
313. Reid J.M., Pendergrass T.W., Krailo M.D., Hammond G.D., Ames M.M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 1990, 50:6525-6528.
314. Rivory L.P., Chatelut E., Canal P., Mathieu-Boue A., Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994, 54:6330-6333.
315. Rosner G.L., Panetta J.C., Innocenti F., Ratain M.J. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther 2008, 84:393-402.
316. 316. Pfizer Inc (2009): Investigator brochure Irinotecan. Pfizer Inc.
317. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994, 54:3723-3725.
318. Dodds H.M., Haaz M.C., Riou J.F., Robert J., Rivory L.P. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998, 286:578-583.
319. Haaz M.C., Rivory L., Riche C., Vernillet L., Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998, 58:468-472.
320. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101:847-854.
321. Thompson P.A., Gupta M., Rosner G.L., Yu A., Barrett J., Bomgaars L., et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol 2008, 62:1027-1037.
322. Bomgaars L.R., Bernstein M., Krailo M., Kadota R., Das S., Chen Z., et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007, 25:4622-4627.
323. Vassal G., Doz F., Frappaz D., Imadalou K., Sicard E., Santos A., et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003, 21:3844-3852.
324. Robert J., Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983, 43:4467-4469.
325. Hempel G., Flege S., Wurthwein G., Boos J. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2002, 49:133-141.
326. Eksborg S., Palm C., Bjork O. A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs 2000, 11:129-136.
327. Frost B.M., Eksborg S., Bjork O., Abrahamsson J., Behrendtz M., Castor A., et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 2002, 38:329-337.
328. Palle J., Frost B.M., Peterson C., Gustafsson G., Hellebostad M., Kanerva J., et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006, 17:385-392.
329. Thompson P.A., Rosner G.L., Matthay K.K., Moore T.B., Bomgaars L.R., Ellis K.J., et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 2009, 64:243-251.
330. Tan C.T., Hancock C., Steinherz P., Bacha D.M., Steinherz L., Luks E., et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res 1987, 47:2990-2995.
331. Dreyer Z.E., Kadota R.P., Stewart C.F., Friedman H.S., Mahoney D.H., Kun L.E., et al. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol 2003, 5:261-267.
332. Foye W.O., Vajragupta O., Sengupta S.K. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides. J Pharm Sci 1982, 71:253-257.
333. Lown J.W., Hanstock C.C., Bradley R.D., Scraba D.G. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol 1984, 25:178-184.
334. Kharasch E.D., Novak R.F. Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracenedione antineoplastic agents. Biochem Biophys Res Commun 1982, 108:1346-1352.
335. Blanz J., Mewes K., Ehninger G., Proksch B., Waidelich D., Greger B., et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos 1991, 19:871-880.
336. Chiccarelli F.S., Morrison J.A., Cosulich D.B., Perkinson N.A., Ridge D.N., Sum F.W., et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986, 46:4858-4861.
337. Alberts D.S., Peng Y.M., Leigh S., Davis T.P., Woodward D.L. Disposition of mitoxantrone in cancer patients. Cancer Res 1985, 45:1879-1884.
338. Mondick J.T., Gibiansky L., Gastonguay M.R., Skolnik J.M., Cole M., Veal G.J., et al. Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 2008, 48:35-42.
339. Veal G.J., Cole M., Errington J., Parry A., Hale J., Pearson A.D., et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005, 11:5893-5899.
340. Chen J., Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 2005, 5:102-112.
341. Bennett W.M., Pastore L., Houghton D.C. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980, 64:921-924.
342. Crooke S.T., Luft F., Broughton A., Strong J., Casson K., Einhorn L. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977, 39:1430-1434.
343. Yee G.C., Crom W.R., Lee F.H., Smyth R.D., Evans W.E. Bleomycin disposition in children with cancer. Clin Pharmacol Ther 1983, 33:668-673.
344. Gietema J.A., Meinardi M.T., Messerschmidt J., Gelevert T., Alt F., Uges D.R., et al. Circulating plasma platinum more than 10years after cisplatin treatment for testicular cancer. Lancet 2000, 355:1075-1076.
345. Townsend D.M., Tew K.D., He L., King J.B., Hanigan M.H. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother 2009, 63:79-85.
346. Bin P., Boddy A.V., English M.W., Pearson A.D., Price L., Tilby M.J., et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res 1994, 14:2279-2283.
347. Peng B., Tilby M.J., English M.W., Price L., Pearson A.D., Boddy A.V., et al. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer 1997, 76:1466-1473.
348. de Jongh F.E., Verweij J., Loos W.J., de W.R., de Jonge M.J., Planting A.S., et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001, 19:3733-3739.
349. Veal G.J., Dias C., Price L., Parry A., Errington J., Hale J., et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001, 7:2205-2212.
350. Bues-Charbit M., Gentet J.C., Bernard J.L., Breant V., Cano J.P., Raybaud C. Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum. Eur J Cancer Clin Oncol 1987, 23:1649-1652.
351. Peng B., English M.W., Boddy A.V., Price L., Wyllie R., Pearson A.D., et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 1997, 33:1823-1828.
352. Loos W.J., de Jongh F.E., Sparreboom A., de W.R., van Boven-van Zomeren D.M., Stoter G., et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006, 24:1499-1506.
353. Goodisman J., Souid A.K. Constancy in integrated cisplatin plasma concentrations among pediatric patients. J Clin Pharmacol 2006, 46:443-448.
354. Veal G.J., Errington J., Tilby M.J., Pearson A.D., Foot A.B., McDowell H., et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Br J Cancer 2007, 96:725-731.
355. Chatelut E., Boddy A.V., Peng B., Rubie H., Lavit M., Dezeuze A., et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996, 59:436-443.
356. Newell D.R., Pearson A.D., Balmanno K., Price L., Wyllie R.A., Keir M., et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 1993, 11:2314-2323.
357. Picton S.V., Keeble J., Holden V., Errington J., Boddy A.V., Veal G.J. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol 2009, 63:749-752.
358. Tonda M.E., Heideman R.L., Petros W.P., Friedman H.S., Murry D.J., Rodman J.H. Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemother Pharmacol 1996, 38:395-400.
359. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6:1205-1218.
360. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002, 1:227-235.
361. Fouladi M., Blaney S.M., Poussaint T.Y., Freeman B.B., McLendon R., Fuller C., et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 2006, 107:2291-2297.
362. Johnson T.N. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005, 59:663-669.
363. Tod M., Jullien V., Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008, 47:231-243.